Allcyte is a pioneer in the field of functional precision oncology. The company provides actionable data on the activity of drug candidates directly in live tissue samples of human cancer patients to support strategic R
Technology transfer, pharmaceutical development for solid dosage forms (tablet, granulates, a.o.) for clinical studies, liquids and creams. Study development and monitoring (Phase I-II), CRO biomarker development for inflammatory and autoimmun diseases, product management for pharmacies, licensing and marketing
APEIRON Biologics AG at a glance: APEIRON Biologics is a privately held European biotech company based in Vienna, Austria, focused on the discovery and development of treatments for respiratory diseases and novel cancer immunotherapies. APEIRON Biologics´ projects and technologies are based on a strong patent portfolio and partnerships with leading pharmaceutical companies and academic institutions.
HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical-stage biopharmaceutical company developing a new class of immunotherapeutics based on its proprietary arenavirus platform that reprograms the body’s immune system.
Origimm (‘Origins of immunity’) is a biotech company that specializes in the discovery of antigens and dermatological drug targets. The company uses its proprietary technology that employs reverse functional screening to discover and develop breakthrough therapies for the prevention and treatment of skin microbiome-associated diseases such as acne vulgaris and other microbiome-associated infections.
What if we could give the body instructions to produce its own drugs? This would be nothing less than a new era in drug therapy and is exactly what messenger RNA (mRNA) could achieve. At ACCANIS, we develop innovative therapeutics for the treatment of common, localized diseases using mRNA. Each cell in your body uses mRNA to translate genetic information into proteins. ACCANIS´ innovative technology takes advantage of this natural mechanism in order to enable effective, on-demand therapeutics.
Vivaldi Biosciences is developing its DeltaFLU influenza vaccine to provide broad cross-protection and superior efficacy in the prophylaxis of seasonal and pandemic influenza. DeltaFLU is composed of influenza vaccine strains genetically modified by deletion of the gene for nonstructural protein 1.
Planta was founded in 1994 by three dynamic biotechnologists whose aim was to put their ideas and visions into practice. Today Planta is an innovative drug development company. Our staff members’ academic backgrounds lie in the fields of biochemistry, biology, pharmacology and toxicology. Our permanent key personal consists of seven co-workers – a group which allows for a compact and familiar atmosphere. Flexibility is our strength and is a great asset to our customers and cooperation partners.
BlueSky Immunotherapies GmbH (Ltd.) is a clinical-stage biotech company. The company’s business is based on its own proprietary, novel technology platform for interferon-inducing viral vectors (delNS). Interferons have immunostimulatory and antiviral properties. BlueSky uses these delNS- mediated properties for therapies against cancer and viral infectious diseases.
Unsere Experten im Bereich Life Science unterstützen Wissenschaftler und Ingenieure dabei, die Herausforderungen in jedem Entwicklungsstadium ihrer Arbeit zu meistern. Unser Angebot umfasst fortschrittlichste Technologien sowie hochwertige Produkte und Lösungen. Anwendung finden diese in der F
Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions. With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.
AOP Orphan Pharmaceuticals AG is an international pharmaceutical company with a focus on rare and special diseases. Over the past 25 years, the company has become an established provider of integrated therapy solutions from its headquarters in Vienna. This has been made possible by a high level of investment in research and development and a strong orientation towards the needs of especially the patients and their families but also the doctors and health care professionals.
F4 Pharma, a clinical-stage biopharmaceutical company developing F06, an anti-inflammatory therapeutic that has shown to improve vascular integrity, FX06 is a substance discovered and developed in the Medical University of Vienna and has a dual mode of action: it is reducing the capillary leak and has anti-inflammatory efficacy. In Covid-19 by reducing pulmonary vascular hyperpermeability, FX06 is supposed to lead to improved lung function and reduced time of mechanical ventilation.
Bayer has core competencies in the fields of health care and nutrition. We address the challenges presented by a growing and aging global population and are committed to drive sustainable development, generate a positive impact with our businesses and create value through innovation and growth. Bayer Austria is a subsidiary of Bayer AG, based in Vienna, where about 190 employees are responsible for marketing, sales, medical information on Bayer-products and clinical studies.